Press Releases May 27, 2026 08:00 AM

Collegium to Participate in 2026 Jefferies Global Healthcare Conference

Collegium Pharmaceutical to present at Jefferies Global Healthcare Conference 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
COLL

Collegium Pharmaceutical announced that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The event, scheduled for June 3, 2026, will include a live webcast available on the company’s website. Collegium is a biopharmaceutical company specializing in treatments for central nervous system and pain conditions, with a portfolio including ADHD medications and pain management products.

Collegium to Participate in 2026 Jefferies Global Healthcare Conference
COLL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Management participation in a high-profile healthcare investor conference highlights company visibility.
  • Live webcast and replay provided, ensuring wide accessibility to investors and analysts.
  • Company’s focus remains on innovative medications for CNS and pain conditions, underscoring its niche in biopharmaceuticals.

STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.

Details of the event are as follows:

Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ET
New York, NY

A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.

With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.

Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com


Risks

  • No new product announcements or clinical data presented may limit immediate investor interest.
  • Broader pharmaceutical and healthcare market volatility could influence stock reaction despite the event.
  • The presentation focuses on company profile and strategy, which may not translate into direct short-term financial gains.

More from Press Releases

CSX Unveils Commemorative Locomotives Marking America’s 250th Anniversary Jun 8, 2026 Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas Jun 8, 2026 FutureCorp Space Acquisition 1 Completes $230,000,000 Initial Public Offering Jun 8, 2026 Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference Jun 8, 2026 HII Partner Bayou Metals Launches Dedicated Manufacturing Line to Accelerate ROMULUS USV Production Jun 8, 2026